Papers by Tadious Chimombe
Journal of Pharmaceutical Research Science & Technology, 2022
Background: Cassia abbreviata Oliv is believed to possess many pharmacological activities and has... more Background: Cassia abbreviata Oliv is believed to possess many pharmacological activities and has been used traditionally to treat many ailments. In Zambia, it is used by traditional healers and the locals to treat various bacterial infections especially in rural areas where traditional medicine is the first or only line of treatment. However, it’s phytochemical content and activity on Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) has not been documented in Zambia. Objective: To investigate the phytochemical composition and antibacterial activity of Cassia abbreviata Oliv stem bark extract against Escherichia coli and Staphylococcus aureus. Materials and Methods: Ethanol and aqueous crude extracts were derived from Cassia abbreviata Oliv stem bark and subjected to qualitative phytochemical screening using standard procedures. The extracts were then used to test for antibacterial activity against standard cultures of E. coli ATCC 25922 and S. ATCC 25923. Ciprofloxa...
Journal of Biomedical Research & Environmental Sciences, 2022
Background: In 2015, Zambia reported 218,200 instances of Diabetes Mellitus (DM) with 8,232 diabe... more Background: In 2015, Zambia reported 218,200 instances of Diabetes Mellitus (DM) with 8,232 diabetes-related fatalities. Insulin therapy and oral antidiabetic medications are two pharmacological therapies used to treat diabetes mellitus. Herbal medicine, on the other hand, has a lengthy history and is an easily accessible and economical therapeutic option. Patients with Type 2 Diabetes Mellitus (T2DM) are increasingly turning to herbal therapies as keeping to conventional regimens becomes more challenging. Aim: We aimed to assess the prevalence and patterns of herbal medicine use among Type 2 diabetes mellitus patients at the University Teaching Hospital. Methods: This cross-sectional study was conducted on 101 T2DM patients using a self-administered questionnaire from August to October 2021. Data were analysed using Statistical Package for Social Science (SPSS) version 26. Results: Of the 101 participants, (n = 93, 92.1%) used herbal medicines. Garlic (Allium sativum) was the most ...
Epidemiology – Open Journal, 2021
Background The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemi... more Background The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemic by the World Health Organization (WHO) on 11th March 2020. Since its emergence in December 2019, there have been challenges in developing drugs that are effective against the virus. Currently, COVID-19 is managed using symptomatic and supportive therapies, antiviral agents, cellular and immunotherapy. Besides, most of the treatment modalities are still under investigation and treatment guidelines vary from one country to another. Ivermectin is among the drugs that are being used as part of treatment guidelines in certain countries like the Republic of Peru. However, the WHO recommends that ivermectin only be used in clinical trials. Aim The authors conducted this review to explore published studies on the possible therapeutic effects of ivermectin against active infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a causative agent of COVID-19. Methods A literat...
RSC Advances
Protean mesoporous silica nanoparticles are propitious candidates over decades for nanoscale drug... more Protean mesoporous silica nanoparticles are propitious candidates over decades for nanoscale drug delivery systems due to their unique characteristics, including changeable pore size, mesoporosity, high drug loading capacity and biodegradability.
Openventio Publishers, 2021
Background
The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemi... more Background
The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemic by the World Health Organization
(WHO) on 11th March 2020. Since its emergence in December 2019, there have been challenges in developing drugs that are effective against the virus. Currently, COVID-19 is managed using symptomatic and supportive therapies, antiviral agents, cellular
and immunotherapy. Besides, most of the treatment modalities are still under investigation and treatment guidelines vary from
one country to another. Ivermectin is among the drugs that are being used as part of treatment guidelines in certain countries like
the Republic of Peru. However, the WHO recommends that ivermectin only be used in clinical trials.
Aim
The authors conducted this review to explore published studies on the possible therapeutic effects of ivermectin against active
infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a causative agent of COVID-19.
Methods
A literature search was conducted using Google Scholar, PubMed and EMBASE for articles published from 2016 to 2021. Search
words used included ivermectin, antiviral, COVID-19, efficacy, safety, dosing, lower mortality rate, hospitalised patients and the
Boolean operator ‘AND’.
Results
A few clinical trials have shown that ivermectin is safe for use in humans at specific doses and reduces the severity of the infection. Ivermectin was seen to reduce the signs and symptoms associated with COVID-19 in some studies while others showed no
significant reduction. However, more studies must be conducted to ascertain its use in treating COVID-19.
Conclusion
Since many clinical trials are being conducted on the use of ivermectin to treat COVID-19, full evidence will be used to support
its use in humans. Currently, some countries that are using ivermectin for treating COVID-19 have reported it to be effective and
reduces morbidity and mortality associated with the disease. Therefore, countries should collaborate and provide full evidence for
the use of ivermectin in humans to manage COVID-19.
Uploads
Papers by Tadious Chimombe
The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemic by the World Health Organization
(WHO) on 11th March 2020. Since its emergence in December 2019, there have been challenges in developing drugs that are effective against the virus. Currently, COVID-19 is managed using symptomatic and supportive therapies, antiviral agents, cellular
and immunotherapy. Besides, most of the treatment modalities are still under investigation and treatment guidelines vary from
one country to another. Ivermectin is among the drugs that are being used as part of treatment guidelines in certain countries like
the Republic of Peru. However, the WHO recommends that ivermectin only be used in clinical trials.
Aim
The authors conducted this review to explore published studies on the possible therapeutic effects of ivermectin against active
infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a causative agent of COVID-19.
Methods
A literature search was conducted using Google Scholar, PubMed and EMBASE for articles published from 2016 to 2021. Search
words used included ivermectin, antiviral, COVID-19, efficacy, safety, dosing, lower mortality rate, hospitalised patients and the
Boolean operator ‘AND’.
Results
A few clinical trials have shown that ivermectin is safe for use in humans at specific doses and reduces the severity of the infection. Ivermectin was seen to reduce the signs and symptoms associated with COVID-19 in some studies while others showed no
significant reduction. However, more studies must be conducted to ascertain its use in treating COVID-19.
Conclusion
Since many clinical trials are being conducted on the use of ivermectin to treat COVID-19, full evidence will be used to support
its use in humans. Currently, some countries that are using ivermectin for treating COVID-19 have reported it to be effective and
reduces morbidity and mortality associated with the disease. Therefore, countries should collaborate and provide full evidence for
the use of ivermectin in humans to manage COVID-19.
The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemic by the World Health Organization
(WHO) on 11th March 2020. Since its emergence in December 2019, there have been challenges in developing drugs that are effective against the virus. Currently, COVID-19 is managed using symptomatic and supportive therapies, antiviral agents, cellular
and immunotherapy. Besides, most of the treatment modalities are still under investigation and treatment guidelines vary from
one country to another. Ivermectin is among the drugs that are being used as part of treatment guidelines in certain countries like
the Republic of Peru. However, the WHO recommends that ivermectin only be used in clinical trials.
Aim
The authors conducted this review to explore published studies on the possible therapeutic effects of ivermectin against active
infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a causative agent of COVID-19.
Methods
A literature search was conducted using Google Scholar, PubMed and EMBASE for articles published from 2016 to 2021. Search
words used included ivermectin, antiviral, COVID-19, efficacy, safety, dosing, lower mortality rate, hospitalised patients and the
Boolean operator ‘AND’.
Results
A few clinical trials have shown that ivermectin is safe for use in humans at specific doses and reduces the severity of the infection. Ivermectin was seen to reduce the signs and symptoms associated with COVID-19 in some studies while others showed no
significant reduction. However, more studies must be conducted to ascertain its use in treating COVID-19.
Conclusion
Since many clinical trials are being conducted on the use of ivermectin to treat COVID-19, full evidence will be used to support
its use in humans. Currently, some countries that are using ivermectin for treating COVID-19 have reported it to be effective and
reduces morbidity and mortality associated with the disease. Therefore, countries should collaborate and provide full evidence for
the use of ivermectin in humans to manage COVID-19.